All manuscripts
Publications NK Cells G-Rex®6M Well Plate

CB derived, optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a Multiple Myeloma model

Published

Share
No image preview

Overview

This poster describes the development of cord blood-derived CD38 CAR-NK cells with CRISPR/Cas9-mediated CD38 knockout. These cells demonstrated potent activity against multiple myeloma. G-Rex® 6M plates were utilized to achieve significant cell expansion (approx. 400-fold).

What this paper found

Cord blood-derived NK cells were engineered non-virally into optimized-affinity CD38 CAR-NK cells with CRISPR/Cas9 CD38 knockout to prevent fratricide, for multiple myeloma. CD3-depleted cord blood mononuclear cells were expanded on irradiated EBV-LCL feeders with IL-2, electroporated with a Cas9 RNP against CD38 on day 5 and with TcBuster transposase mRNA plus a nanoplasmid carrying the CAR on day 7, then harvested on day 22. The product was over 96% CD56-positive, CD3-negative NK cells with over 85% CD38 knockout, over 80% transgene expression and 1 to 2 vector copies per cell. In G-Rex®6M plates the cells expanded about 400-fold by day 22. They killed MM.1S, H929, RPMI and NALM6 cells in vitro and, in NSG mice bearing MM.1S-LUC myeloma, reduced tumour burden and improved survival versus control NK cells and vehicle.

Note: In vivo data come from NSG mice inoculated with MM.1S-LUC cells and treated on days 2 and 9 with IL-15 support, five mice per group; the authors state that dose, schedule and safety still need to be optimized.

Using G-Rex6M plates, CD38 CAR-NK cells with CD38 KO expanded approximately 400 fold by D22. — S Brophy, L Kirkham McCarthy, M Köylijärvi, D Hardwicke, H Hintz, N Otto, B Ettestad, D Hermanson, E Shevlin, M Reilly, M O’Dwyer

Study details

Authors
S Brophy, L Kirkham McCarthy, M Köylijärvi, D Hardwicke, H Hintz, N Otto, B Ettestad, D Hermanson, E Shevlin, M Reilly, M O’Dwyer
Institution
ONK Therapeutics · Bio-Techne
Year
2022
G-Rex® model(s)
G-Rex®6M Well Plate
Cell type(s)
NK Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

After CD38 knockout and TcBuster transposition of the CAR, the CD38 CAR-NK cells were expanded in G-Rex®6M plates, where they grew approximately 400-fold by day 22, when they were harvested and cryopreserved. Extending the culture to day 27 added a further 4 to 8-fold expansion.

Ecosystem products: TcBuster

Explore related

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →